Covered recipient · General Payments record
RALPH J HAUKE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$7,629.00
9 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,750.00 | 1 |
| Food and Beverage | $469.00 | 5 |
| Travel and Lodging | $410.00 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $7,342.00 | 5 |
| Advanced Accelerator Applications | $271.54 | 3 |
| Sirtex Medical Inc | $15.46 | 1 |
Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RALPH J HAUKE
NPI 1578511283 · CMS profile ID 297671
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
OMAHA, NE
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1578511283?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578511283?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578511283?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1578511283?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
9 matching records · $7,629.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–9 of 9.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Sirtex Medical Inc | $15.46 | 06/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698371209 | CMS |
| Advanced Accelerator Applications | $15.01 | 05/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704526547 | CMS |
| Advanced Accelerator Applications | $121.12 | 05/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 708348561 | CMS |
| Astellas Pharma US Inc | $291.00 | 03/07/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655597085 | CMS |
| Astellas Pharma US Inc | $182.00 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655597088 | CMS |
| Astellas Pharma US Inc | $23.00 | 03/07/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655597091 | CMS |
| Astellas Pharma US Inc | $96.00 | 03/07/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655597095 | CMS |
| Advanced Accelerator Applications | $135.41 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 708348225 | CMS |
| Astellas Pharma US Inc | $6,750.00 | 02/05/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655597081 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $609.30 | 2 |
| PY2025 | Principal investigator | $1,167,738.55 | 292 |
| PY2024 | Principal investigator | $1,299,594.58 | 212 |
| PY2023 | Principal investigator | $2,735,258.21 | 252 |
| PY2022 | Recipient | $4,157.00 | 1 |
| PY2022 | Principal investigator | $1,567,591.67 | 137 |
| PY2021 | Principal investigator | $2,060,900.77 | 213 |
| PY2020 | Recipient | $705.81 | 1 |
| PY2020 | Principal investigator | $1,867,000.72 | 289 |
| PY2019 | Principal investigator | $1,377,455.65 | 354 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
252 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2023 | Non-covered Recipient Entity ONCHEMATOLOGY WEST PC | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab | No dispute reported | 06/30/2026 | 998415461 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $12,884.98 | 12/31/2023 | Non-covered Recipient Entity Oncology Hematology West, PC DBA Nebraska Cancer Specialists | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 | No dispute reported | 06/30/2026 | 1042497519 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,002.36 | 12/31/2023 | Non-covered Recipient Entity Oncology Hematology West, PC DBA Nebraska Cancer Specialists | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 | No dispute reported | 06/30/2026 | 1042497521 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,149.80 | 12/31/2023 | Non-covered Recipient Entity Oncology Hematology West, PC DBA Nebraska Cancer Specialists | A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma | No dispute reported | 06/30/2026 | 1042497995 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $12,406.40 | 12/31/2023 | Non-covered Recipient Entity Oncology Hematology West, PC DBA Nebraska Cancer Specialists | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 1042498429 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $117,169.49 | 12/31/2023 | Non-covered Recipient Entity Oncology Hematology West, PC DBA Nebraska Cancer Specialists | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 1042498431 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $14.43 | 12/31/2023 | Non-covered Recipient Entity Nebraska Cancer Specialists | A Phase 2, Randomized, Double-Blind Study of Pembrolizumab MK-3475 plus Epacadostat INCB024360 Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1 | No dispute reported | 06/30/2026 | 1042498733 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,252.29 | 12/31/2023 | Non-covered Recipient Entity Oncology Hematology West, PC DBA Nebraska Cancer Specialists | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 | No dispute reported | 06/30/2026 | 1042513425 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,843.51 | 12/31/2023 | Non-covered Recipient Entity Oncology Hematology West, PC DBA Nebraska Cancer Specialists | A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy KEYNOTE-B98 | No dispute reported | 06/30/2026 | 1042520331 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $16,353.74 | 12/31/2023 | Non-covered Recipient Entity Oncology Hematology West, PC DBA Nebraska Cancer Specialists | A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 | No dispute reported | 06/30/2026 | 1042521461 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,503.72 | 12/31/2023 | Non-covered Recipient Entity Oncology Hematology West, PC DBA Nebraska Cancer Specialists | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1042536321 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $21,932.52 | 12/31/2023 | Non-covered Recipient Entity Oncology Hematology West, PC DBA Nebraska Cancer Specialists | A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 | No dispute reported | 06/30/2026 | 1042542035 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $272,139.42 | 12/31/2023 | Non-covered Recipient Entity Oncology Hematology West, PC DBA Nebraska Cancer Specialists | A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 | No dispute reported | 06/30/2026 | 1042542741 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,131.70 | 12/21/2023 | Non-covered Recipient Entity Oncology Hematology West P.c. Dba Nebraska Cancer Specialists | A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1061177658 |
| Principal investigator 1 | Astellas Pharma Global Development | $464.00 | 12/19/2023 | Covered Recipient Teaching Hospital Nebraska Methodist Hospital | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1022250223 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,675.70 | 12/14/2023 | Non-covered Recipient Entity QCCA NETWORK LLC | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049070025 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,374.65 | 12/14/2023 | Non-covered Recipient Entity QCCA NETWORK LLC | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049070035 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $106,500.00 | 12/01/2023 | Non-covered Recipient Entity Oncology Hematology West P.C. dba Nebraska Cancer Specialists | An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1042564967 |
| Principal investigator 1 | MACROGENICS, INC. | $6,317.00 | 11/29/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST P C | A STUDY OF TWO DOSE LEVELS OF VOBRAMITAMAB DUOCARMAZINE IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1043830595 |
| Principal investigator 1 | BioNTech SE | $250.00 | 11/28/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060315339 |
| Principal investigator 1 | Astellas Pharma Global Development | $5,063.00 | 11/24/2023 | Covered Recipient Teaching Hospital Nebraska Methodist Hospital | A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1022250245 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,400.00 | 11/20/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156527 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $16,963.20 | 11/16/2023 | Non-covered Recipient Entity Bon Secours-st Francis Hospital | A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1027480049 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $23,203.20 | 11/16/2023 | Non-covered Recipient Entity Oncology Hematology West P.c. Dba Nebraska Cancer Specialists | A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1027480999 |
| Principal investigator 1 | MACROGENICS, INC. | $80.00 | 11/14/2023 | Non-covered Recipient Entity ADVARRA INC | A STUDY OF TWO DOSE LEVELS OF VOBRAMITAMAB DUOCARMAZINE IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1043830357 |
| Principal investigator 1 | MACROGENICS, INC. | $395.00 | 11/14/2023 | Non-covered Recipient Entity ADVARRA INC | A STUDY OF TWO DOSE LEVELS OF VOBRAMITAMAB DUOCARMAZINE IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1043830427 |
| Principal investigator 1 | MACROGENICS, INC. | $1,040.00 | 11/14/2023 | Non-covered Recipient Entity ADVARRA INC | A STUDY OF TWO DOSE LEVELS OF VOBRAMITAMAB DUOCARMAZINE IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1043830441 |
| Principal investigator 1 | BioNTech SE | $3,564.05 | 11/07/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060315293 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,675.70 | 10/26/2023 | Non-covered Recipient Entity QCCA NETWORK LLC | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049069975 |
| Principal investigator 1 | BioNTech SE | $98.00 | 10/17/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060315333 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $87,763.00 | 10/16/2023 | Non-covered Recipient Entity Oncology Hematology West, PC dba Nebraska Cancer Specialists | A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 | No dispute reported | 06/30/2026 | 1042542029 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,250.00 | 10/11/2023 | Non-covered Recipient Entity Oncology Hematology West, PC dba Nebraska Cancer Specialists | A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 | No dispute reported | 06/30/2026 | 1042521507 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,374.65 | 10/06/2023 | Non-covered Recipient Entity QCCA NETWORK LLC | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049069943 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,374.65 | 10/06/2023 | Non-covered Recipient Entity QCCA NETWORK LLC | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049069953 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,675.70 | 10/06/2023 | Non-covered Recipient Entity QCCA NETWORK LLC | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049069963 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,360.00 | 10/02/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156525 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,627.00 | 09/26/2023 | Covered Recipient Teaching Hospital Nebraska Methodist Hospital | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1022250209 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,322.00 | 09/15/2023 | Covered Recipient Teaching Hospital Nebraska Methodist Hospital | A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1022250234 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,500.00 | 09/12/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | Fixed dose IV combination of atezo tira | No dispute reported | 06/30/2026 | 1040409765 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $18,000.00 | 09/12/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS | Fixed dose IV combination of atezo tira | No dispute reported | 06/30/2026 | 1040409779 |
| Principal investigator 1 | BioNTech SE | $1,149.20 | 09/01/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060319497 |
| Principal investigator 1 | BioNTech SE | $276.00 | 08/23/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060314993 |
| Principal investigator 1 | BioNTech SE | $8,359.00 | 08/23/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060314999 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,250.00 | 08/16/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1022255671 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $255.36 | 08/08/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY | An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) | No dispute reported | 06/30/2026 | 1017197913 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,400.00 | 08/07/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156523 |
| Principal investigator 1 | BioNTech SE | $2,298.40 | 08/01/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060315001 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,374.65 | 07/27/2023 | Non-covered Recipient Entity QUALITY CANCER CARE ALLIANCE | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049070077 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,675.70 | 07/27/2023 | Non-covered Recipient Entity QUALITY CANCER CARE ALLIANCE | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049070087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,374.00 | 07/17/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156521 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,250.00 | 07/17/2023 | Non-covered Recipient Entity Oncology Hematology West, PC dba Nebraska Cancer Specialists | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1042536311 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $878.41 | 07/05/2023 | Non-covered Recipient Entity Us Oncology Research Llc | Bay88-8223 Alpharadin Combo with abiraterone in CRPC | No dispute reported | 06/30/2026 | 1000204629 |
| Principal investigator 1 | BioNTech SE | $750.00 | 07/04/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060314995 |
| Principal investigator 1 | BioNTech SE | $1,500.00 | 07/04/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060314997 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,374.65 | 06/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049065849 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,675.70 | 06/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049065863 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,675.70 | 06/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049065873 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,675.70 | 06/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049065883 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,675.70 | 06/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049065895 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,374.65 | 06/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049065903 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,675.70 | 06/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049065915 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,374.65 | 06/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049065925 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $127.67 | 06/30/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049065935 |
| Principal investigator 1 | BioNTech SE | $1,149.20 | 06/28/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060318137 |
| Principal investigator 1 | BioNTech SE | $3,000.00 | 06/22/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060318139 |
| Principal investigator 1 | BioNTech SE | $1,500.00 | 06/22/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060318145 |
| Principal investigator 1 | BioNTech SE | $3,750.00 | 06/22/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060319749 |
| Principal investigator 1 | BioNTech SE | $1,000.00 | 06/22/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060319751 |
| Principal investigator 1 | Janssen Research & Development, LLC | $724.00 | 06/19/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156517 |
| Principal investigator 1 | Janssen Research & Development, LLC | $256.00 | 06/19/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156519 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453569 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453575 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453583 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453589 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453595 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453603 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453609 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453615 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453621 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453627 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453631 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453637 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453643 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453649 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453655 |
| Principal investigator 1 | Eisai Inc. | $520.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453663 |
| Principal investigator 1 | Eisai Inc. | $35.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453669 |
| Principal investigator 1 | Eisai Inc. | $35.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453675 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453681 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453687 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453693 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453699 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453705 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453711 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453717 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453723 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453729 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453735 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453741 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453747 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453754 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453761 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453767 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453773 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453779 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453785 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453791 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453797 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453803 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453809 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453815 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453821 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453827 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453833 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453841 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453847 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453853 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453859 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453865 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453871 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453877 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453883 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453889 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453895 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453901 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453907 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453913 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453919 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453925 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453931 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453937 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453943 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453949 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453955 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453961 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453967 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453973 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453979 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453985 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453991 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453997 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454003 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454009 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454015 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454021 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454027 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454035 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454041 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454047 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454053 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454059 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454065 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454071 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454077 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454083 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454089 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454095 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454101 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454107 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454113 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454119 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454125 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454131 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454137 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454143 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454147 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454153 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454159 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454165 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454171 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454177 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454183 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454189 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454195 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454201 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454205 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454211 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454217 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454223 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454229 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454235 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454241 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454247 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454253 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454259 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454263 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454269 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454277 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454283 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454289 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454295 |
| Principal investigator 1 | Eisai Inc. | $200.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454303 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454309 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454315 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454323 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454329 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454335 |
| Principal investigator 1 | Eisai Inc. | $15.00 | 06/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025454341 |
| Principal investigator 1 | BioNTech SE | $1,160.00 | 06/08/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060318143 |
| Principal investigator 1 | BioNTech SE | $276.00 | 06/08/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060318147 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 06/05/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156515 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,322.00 | 06/02/2023 | Covered Recipient Teaching Hospital Nebraska Methodist Hospital | A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1022250269 |
| Principal investigator 1 | BioNTech SE | $2,298.40 | 05/30/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060319753 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,603.80 | 05/04/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049062961 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,675.70 | 05/04/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049062971 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $3,489.75 | 05/04/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049062985 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,374.65 | 05/04/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049062995 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,385.45 | 05/04/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049063004 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,675.70 | 05/04/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049063015 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $3,489.75 | 05/04/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049063026 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,603.80 | 05/04/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049063507 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,374.65 | 05/04/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049063517 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,385.45 | 05/04/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049063527 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,505.60 | 05/04/2023 | Non-covered Recipient Entity DANA-FARBER CANCER CARE NETWORK, INC. | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1049063543 |
| Principal investigator 1 | BioNTech SE | $14,398.00 | 05/03/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060318141 |
| Principal investigator 1 | BioNTech SE | $1,149.20 | 05/03/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060319747 |
| Principal investigator 1 | Janssen Research & Development, LLC | $934.00 | 05/01/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156511 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,400.00 | 05/01/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156513 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $105,791.50 | 04/24/2023 | Non-covered Recipient Entity Nebraska Cancer Specialists | Phase III 1L Melanoma non-inferiority rela+nivo FDC SubQ vs. rela+nivo FDC IV | No dispute reported | 06/30/2026 | 1027480797 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,574.00 | 04/17/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156509 |
| Principal investigator 1 | Eisai Inc. | $956.00 | 04/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453563 |
| Principal investigator 1 | BioNTech SE | $3,447.60 | 04/04/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060319745 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 04/03/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEB | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab | No dispute reported | 06/30/2026 | 998376227 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 04/03/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEB | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab | No dispute reported | 06/30/2026 | 998376229 |
| Principal investigator 1 | ABBVIE INC. | $1,800.00 | 04/03/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEB | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab | No dispute reported | 06/30/2026 | 998376231 |
| Principal investigator 1 | ABBVIE INC. | $12,000.00 | 04/03/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC DBA NEB | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab | No dispute reported | 06/30/2026 | 998376233 |
| Principal investigator 1 | BioNTech SE | $1,049.00 | 03/24/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060319151 |
| Principal investigator 1 | BioNTech SE | $7,586.00 | 03/24/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060319153 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $57,312.00 | 03/16/2023 | Non-covered Recipient Entity Us Oncology Res Llc | Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS & 9th DMC) | No dispute reported | 06/30/2026 | 1027458197 |
| Principal investigator 1 | Exelixis Inc. | $867.85 | 03/03/2023 | Non-covered Recipient Entity Oncology Hematology West, P.C. | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | No dispute reported | 06/30/2026 | 1041938935 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $21,395.87 | 03/01/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST NEBRASKA CANCER SPECIALIST | PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1017235049 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,250.00 | 02/26/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1025376919 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,250.00 | 02/26/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1025376925 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $196.42 | 02/23/2023 | Non-covered Recipient Entity Nebraska Cancer Specialists | Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS) | No dispute reported | 06/30/2026 | 1027451555 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $36,027.50 | 02/23/2023 | Non-covered Recipient Entity Oncology Hematology West P.c. Dba Nebraska Cancer Specialists | A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1027480987 |
| Principal investigator 1 | Astellas Pharma Global Development | $6,644.00 | 02/22/2023 | Covered Recipient Teaching Hospital Nebraska Methodist Hospital | A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1022250257 |
| Principal investigator 1 | BioNTech SE | $196.00 | 02/22/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060319149 |
| Principal investigator 1 | BioNTech SE | $6,895.20 | 02/16/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST PC | Pre-commercial | No dispute reported | 06/30/2026 | 1060319147 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,208.00 | 02/07/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156505 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,374.00 | 02/07/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH INC | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 986156507 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,250.00 | 02/02/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1025376899 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,250.00 | 02/02/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1025376905 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,250.00 | 02/02/2023 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1025376913 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $42.00 | 01/26/2023 | Non-covered Recipient Entity Oncology Hematology West P.c. Dba Nebraska Cancer Specialist | PhII 1L NSCLC Dose Safety, CoC Biomarker Evaluation - A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage | No dispute reported | 06/30/2026 | 1027480973 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $149.40 | 01/26/2023 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1017220897 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,977.40 | 01/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, P.C. | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community | No dispute reported | 06/30/2026 | 991127713 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $31,415.00 | 01/15/2023 | Non-covered Recipient Entity Oncology Hematology West P.c. Dba Nebraska Cancer Specialists | Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS) | No dispute reported | 06/30/2026 | 1027452483 |
| Principal investigator 1 | Eisai Inc. | $956.00 | 01/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | No dispute reported | 06/30/2026 | 1025453557 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $36.63 | 01/15/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY | A randomized double blind placebo controlled phase III study comparing the combination of PDR001 dabrafenib and trametinib versus placebo dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma | No dispute reported | 06/30/2026 | 1017198287 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $834,244.61 | 01/11/2023 | Non-covered Recipient Entity NEBRASKA CANCER SPECIALISTS | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1017199779 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $645,032.43 | 01/05/2023 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY WEST NEBRASKA CANCER SPECIALIST | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1017233169 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,062.00 | 01/04/2023 | Non-covered Recipient Entity Oncology Hematology West, PC dba Nebraska Cancer Specialists | A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy KEYNOTE-B98 | No dispute reported | 06/30/2026 | 1042520161 |